GoodRx Holdings, Inc.
NASDAQ:GDRXMedical - Healthcare Information Services
+$0.05 today
- Market cap
- $1.15B
- Beta
- 1.61
- P/E (TTM)
- 44.0
- EPS (TTM)
- $0.06
Volume 0.66M
Average 1.61M
GDRX Net Income
Bottom-line profit after all expenses, interest, and taxes.
GoodRx Holdings, Inc.NASDAQ: GDRX
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income declines year over year
Q1 FY2026 net income of $1.17M fell 89.4% year over year, behind the -44.1% change in trailing-twelve-month net income. Sequentially, it fell 78.5% from the prior quarter.
Context
- Net income amounted to 3.8% of revenue in FY2025, up 1.8 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 10 analysts of $102.79M (+237.7%) for the fiscal year ending Dec 2026, a step up from the +85.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $1.17M-78.5% QoQ
- Last fiscal yearDec 2025
- $30.44M+85.7% YoY
- LTMMar 2026
- $20.56M-44.1% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -89.4% | +116.0% | +205.4 pp |
| 1 year | +85.7% | +237.7% | +152.0 pp |
| 3-year CAGR | — | +62.4% | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the income statement
- Latest · FY2025
- 30.44M USD
- Year-over-year change
- +85.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 30.44M | +85.7% |
| FY2024 | 2024-12-31 | 16.39M | +284.8% |
| FY2023 | 2023-12-31 | (8.87M) | +73.0% |
| FY2022 | 2022-12-31 | (32.83M) | -30.0% |
| FY2021 | 2021-12-31 | (25.25M) | — |
Net Income vs competitors
How GDRX compares with its peers on the latest reported figures
- GDRX's LTM Mar 2026 net income of $20.56M is the highest of the 4 companies compared; the peer median is -$87.88M.
- Its year-over-year change of -44.1% is the 3rd highest of 4, against a peer median of +43.2%.
- Net income amounts to 2.6% of revenue for GDRX, versus a peer median of 7.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.56M | -44.1% | — | 2.6% | |
| LTM Mar 2026 | -$16.25M | -58.5% | — | 7.4% | |
| LTM Mar 2026 | -$87.88M | +43.2% | — | 37.0% | |
| LTM Mar 2026 | -$171.15M | +83.1% | — | 6.8% | |
| Peer median (excluding GDRX) | -$87.88M | +43.2% | — | 7.4% | |
Competitors are the stored peer set for GDRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 745.42M | 766.55M | 750.27M | 792.32M | 796.85M |
| Cost of Revenue | 46.72M | 65.08M | 66.93M | 48.22M | 57.6M |
| Gross Profit | 698.71M | 701.48M | 683.34M | 744.11M | 739.26M |
| Gross Margin | 93.7% | 91.5% | 91.1% | 93.9% | 92.8% |
| Research & Development | 125.86M | 143.14M | 135.84M | 123.75M | 121.03M |
| Selling, General & Admin | 524.9M | 502.42M | 466.84M | 484.98M | 445.52M |
| Operating Expenses | 685.3M | 699.74M | 710.35M | 678.26M | 651.76M |
| Depreciation & Amortization | 34.54M | 54.18M | 107.67M | 69.54M | 85.22M |
| EBITDA | 48M | 65.19M | 108.82M | 153.92M | 184.36M |
| EBITDA Margin | 6.4% | 8.5% | 14.5% | 19.4% | 23.1% |
| Operating Income | 13.41M | 1.74M | (27.01M) | 65.85M | 87.49M |
| Operating Margin | 1.8% | 0.2% | -3.6% | 8.3% | 11.0% |
| Interest Income | 59K | 9.27M | 32.17M | 23.27M | 10.93M |
| Interest Expense | 23.64M | 34.24M | 56.73M | 52.92M | 42.61M |
| Other Income / Expenses | (23.58M) | (24.97M) | (28.57M) | (34.39M) | (30.95M) |
| Income Before Tax | (10.18M) | (23.23M) | (55.57M) | 31.46M | 56.54M |
| Pre-Tax Margin | -1.4% | -3.0% | -7.4% | 4.0% | 7.1% |
| Income Tax Expense | 15.08M | 9.6M | (46.7M) | 15.07M | 26.1M |
| Net Income | (25.25M) | (32.83M) | (8.87M) | 16.39M | 30.44M |
| Net Margin | -3.4% | -4.3% | -1.2% | 2.1% | 3.8% |
| EPS (Basic) | (0.06) | (0.08) | (0.02) | 0.04 | 0.09 |
| EPS (Diluted) | (0.06) | (0.08) | (0.02) | 0.04 | 0.09 |
| Weighted Avg Shares | 409.98M | 412.86M | 410.32M | 385.74M | 356.33M |
| Weighted Avg Shares (Diluted) | 409.98M | 412.86M | 410.32M | 392.17M | 356.97M |
GoodRx Holdings, Inc.
NASDAQ:GDRX
Intrinsic Alpha fair value
Locked
Current Price
$3.36
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.